International differences in treatment and clinical outcomes for high grade glioma

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Chien, Li Nien ^a   Ostrom, Quinn T ^b   Gittleman, Haley ^b   Lin, Jia Wei ^a,c   Sloan, Andrew E ^d   Barnett, Gene H ^e   Elder, J Bradley ^f   McPherson, Christopher ^a   Warnick, Ronald ^a   Chiang, Yung Hsiao ^a,g   Lin, Chieh Min ^a,c   Rogers, Lisa R ^d   Chiou, Hung Yi ^a   Barnholtz Sloan, Jill S ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e NEUROLOGICAL INSTITUTE   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMORBIDITY; ETHNIC DIFFERENCE; FEMALE; GEOGRAPHIC DISTRIBUTION; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TAIWAN; UNITED STATES; ADOLESCENT; BRAIN NEOPLASMS; ETHNOLOGY; MIDDLE AGED; OHIO; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; OHIO; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

EID: 84936852323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129602     Document Type: Article

References (37)

1. Mrugala MM. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discovery medicine. 2013; 15(83):221-30. Epub 2013/05/03. PMID: 23636139.
2. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16(s4):iv1-iv63. doi: 10.1093/neuonc/nou223 PMID: 25304271
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 2005; 352(10):987-96. doi: 10.1056/NEJMoa043330 PMID: 15758009.
4. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials. Journal of the National Cancer Institute. 1993; 85(9):704-10. doi: 10.1093/jnci/85.9.704 PMID: 8478956
5. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. Journal of Neurosurgery. 2003; 99(3):467-73. doi: 10.3171/jns.2003.99.3.0467 PMID: 12959431.
6. Buckner JC. Factors influencing survival in high-grade gliomas. Seminars in Oncology. 2003; 30, Supplement 19(0):10-4. doi: 10.1053/j.seminoncol.2003.11.031
7. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. Journal of Neurosurgery. 2009; 110(1):156-62. doi: 10.3171/2008.4.17536 PMID: 18847342.
8. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain. 2007; 130(10):2596-606. doi: 10.1093/brain/awm204 PMID: 17785346
9. Huang Y-C, Wei K-C, Chang C-H, Yang J-T, Ho J-T, Shen C-C, et al. A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan. Journal of Clinical Neuroscience. 2011; 18(6):784-8. doi: 10.1016/j.jocn.2010.10.016 PMID: 21507649
10. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology. 2006; 7(5):392-401. doi: 10.1016/S1470-2045(06)70665-9 PMID: 16648043
11. Asthagiri AR, Pouratian N, Sherman J, Ahmed G, Shaffrey ME. Advances in Brain Tumor Surgery. Neurologic Clinics. 2007; 25(4):975-1003. doi: 10.1016/j.ncl.2007.07.006 PMID: 17964023
12. Wen PY, Kesari S. Malignant Gliomas in Adults. New England Journal of Medicine. 2008; 359(5):492-507. doi: 10.1056/NEJMra0708126 PMID: 18669428.
13. Stupp R, Tonn J-C, Brada M, Pentheroudakis G, Group ObotEGW. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2010; 21(suppl 5):v190-v3. doi: 10.1093/annonc/mdq187 PMID: 20555079
14. Farina P, Lombardi G, Bergo E, Roma A, Zagonel V. Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature. BioMed Research International. 2014; 2014:9. doi: 10.1155/2014/734281
15. Ray S, Bonafede MM, Mohile NA. Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population. American health & drug benefits. 2014; 7(3):140-9. Epub 2014/07/06. PMID: 24991398; PubMed Central PMCID: PMCPMC4070631.
16. Ostrom QT, McCulloh C, Chen Y, Devine K, Wolinsky Y, Davitkov P, et al. Family history of cancer in benign brain tumor subtypes versus gliomas. Front Oncol. 2012; 2:19. doi: 10.3389/fonc.2012.00019 PMID: 22649779; PubMed Central PMCID: PMC3355899.
17. Chiang C-J, Chen Y-C, Chen C-J, You S-L, Lai M-S. Cancer Trends in Taiwan. Japanese Journal of Clinical Oncology. 2010; 40(10):897-904. doi: 10.1093/jjco/hyq057 PMID: 20495192
18. National Health Insurance Administration MoHaW. 2013 [updated 2012/10/29]. Available: http://www.nhi.gov.tw/english/.
19. Lu T-H, Lee M-C, Chou M-C. Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. International Journal of Epidemiology. 2000; 29(2):336-43. doi: 10.1093/ije/29.2.336 PMID: 10817134
20. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. The Lancet Oncology. 2014; 15(9):e395-e403. doi: 10.1016/S1470-2045(14)70011-7 PMID: 25079102
21. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of Chemotherapy for Advanced Lung Cancer in the Elderly: Instrumental Variable and Propensity Analysis. Journal of Clinical Oncology. 2001; 19(4):1064-70. PMID: 11181670
22. Koppie TM, Serio AM, Vickers AJ, Vora K, Dalbagni G, Donat SM, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008; 112(11):2384-92. doi: 10.1002/cncr.23462 PMID: 18404699
23. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer. Journal of Clinical Oncology. 2011; 29(10):1335-41. doi: 10.1200/jco.2010.31.2330 PMID: 21357791
24. Giordano SH, Duan Z, Kuo Y-F, Hortobagyi GN, Goodwin JS. Use and Outcomes of Adjuvant Chemotherapy in Older Women With Breast Cancer. Journal of Clinical Oncology. 2006; 24(18):2750-6. doi: 10.1200/jco.2005.02.3028 PMID: 16782915
25. Institute Nc. SEER-Medicare: Calculation of Comorbidity Weights 2013 [updated 10/18/2013; cited 2014 8/4]. Available from: http://appliedresearch.cancer.gov/seermedicare/program/comorbidity.html.
26. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005; 293(5):557-64. doi: 10.1001/jama.293.5.557 PMID: 15687310
27. Bhoo-Pathy N, Yip CH, Hartman M, Uiterwaal CS, Devi BC, Peeters PH, et al. Breast cancer research in Asia: adopt or adapt Western knowledge? European journal of cancer (Oxford, England: 1990). 2013; 49(3):703-9. Epub 2012/10/09. doi: 10.1016/j.ejca.2012.09.014 PMID: 23040889.
28. Bauchet L, Zouaoui S, Darlix A, Menjot de Champfleur N, Ferreira E, Fabbro M, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro Oncol. 2014. doi: 10.1093/neuonc/nou063 PMID: 24792440.
29. Oike T, Suzuki Y, Sugawara K, Shirai K, Noda SE, Tamaki T, et al. Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PloS one. 2013; 8(11):e78943. Epub 2013/11/23. doi: 10.1371/journal.pone.0078943 PMID: 24265731; PubMed Central PMCID: PMCPMC3827088.
30. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6(7):2585-97. Epub 2000/07/29. PMID: 10914698.
31. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. New England Journal of Medicine. 2014; 370(8):699-708. doi: 10.1056/NEJMoa1308573 PMID: 24552317.
32. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England journal of medicine. 2014; 370(8):709-22. doi: 10.1056/NEJMoa1308345 PMID: 24552318.
33. Tomimatsu N, Mukherjee B, Catherine Hardebeck M, Ilcheva M, Vanessa Camacho C, Louise Harris J, et al. Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice. Nat Commun. 2014; 5. doi: 10.1038/ncomms4561
34. Gil del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, et al. Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma. Clinical Cancer Research. 2014; 20(5):1235-48. doi: 10.1158/1078-0432.ccr-13-1607 PMID: 24366691
35. Camacho CV, Todorova PK, Hardebeck MC, Tomimatsu N, Gil del Alcazar CR, Ilcheva M, et al. DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. Oncogene. 2014. doi: 10.1038/onc.2014.29
36. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8):765-73. doi: 10.1056/NEJMoa0808710 PMID: 19228619; PubMed Central PMCID: PMC2820383.
37. Shonka NA, Theeler B, Cahill D, Yung A, Smith L, Lei X, et al. Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. Journal of neuro-oncology. 2013; 113(2):305-11. doi: 10.1007/s11060-013-1116-4 PMID: 23526410.